Laura Dietch Net Worth

Laura Dietch biography

Laura N. Dietch serves as Independent Director of the Company. Ms. Dietch has more than twenty-five years of experience in the medical device industry as a Chief Executive Officer, company co-founder, director, fundraiser, inventor, and mentor. She is currently the President and Chief Executive Officer of BioTrace Medical, Inc., a commercial stage cardiovascular medical device company, which she co-founded and has led from its inception in 2013. Ms. Dietch has gained extensive executive and operating experience in both private and public companies, having been a member of the senior management team in several start-up and Fortune 500 companies, including Progressive Angioplasty Systems, LuMend and Medtronic. Ms. Dietch is also an active angel investor as well as a past director and current member of Life Science Angels and has sat on that group’s Medical Devices Committee for the past ten years.

What is the salary of Laura Dietch?

As the Independent Director of HeartBeam Inc, the total compensation of Laura Dietch at HeartBeam Inc is $161,298. There are 12 executives at HeartBeam Inc getting paid more, with Joseph Capper having the highest compensation of $4,133,160.

How old is Laura Dietch?

Laura Dietch is 62, she's been the Independent Director of HeartBeam Inc since 2019. There are 11 older and 6 younger executives at HeartBeam Inc. The oldest executive at HeartBeam Inc is Robert Rubin, 74, who is the Independent Director.

What's Laura Dietch's mailing address?

Laura's mailing address filed with the SEC is 1000 CEDAR HOLLOW ROAD, , MALVERN, PA, 19355.

Insiders trading at HeartBeam Inc

Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz y Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.

What does HeartBeam Inc do?

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.

HeartBeam Inc executives and stock owners

HeartBeam Inc executives and other stock owners filed with the SEC include:

• Joseph Capper,
  President, Chief Executive Officer, Director
• Heather Getz,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer
• Fred Broadway,
  President, BioTel Heart
• Daniel Wisniewski,
  Senior Vice President - Technical Operations
• Kirk Gorman,
  Independent Chairman of the Board
• Rebecca Rimel,
  Independent Director
• Anthony Conti,
  Independent Director
• Joseph Frick,
  Independent Director
• Stephan Rietiker,
  Director
• Robert Rubin,
  Independent Director
• Colin Hill,
  Independent Director
• Tiffany Olson,
  Independent Director
• Laura Dietch,
  Independent Director
• Dr. Branislav Vajdic Ph.D.,
  Founder, CEO & Director
• Richard D. Brounstein,
  Chief Financial Officer
• Manish Wadhwa,
  Chief Medical Officer
• Andrei Stoica,
  Chief Technology Officer
• Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
  Chief Medical Officer
• Ken Persen,
  Chief Technology Officer
• Dr. Jon Hunt Ph.D.,
  Exec. VP & Chief Bus. Officer
• Alexei Shvilkin M.D.,
  Chief Medical Officer
• Dr. Dorin Panescu Ph.D.,
  Chief Technical Officer
• Alan Baumel,
  Chief Operating Officer
• Richard M. Ferrari,
  Exec. Chairman
• George Hrenko,
  Senior Vice President
• Stephen Rietiker,
  Director
• Michael Geldart,
  Senior Vice President
• Ronald A Ahrens,
  Director
• Eric N Prystowsky,
  Director
• Peter Ferola,
  SVP & General Counsel
• Kenneth Warwick Iii Nelson,
  Director
• Mark E Strome,
  10% owner
• Michael R Jaff,
  Director
• Willem Elfrink,
  Director
• Marga Ortigas Wedekind,
  Director
• Urioste George De,
  Director
• Richard Ferrari,
  Director
• Jon Patrick Hunt,
  Chief Business Officer
• Richard Brounstein,
  Chief Financial Officer
• Alan Baumel,
  Chief Operating Officer
• Kenneth Harry Persen,
  Chief Technology Officer
• Robert Paul Eno,
  President
• Branislav Vajdic,
  CHIEF EXECUTIVE OFFICER